BioNxt Solutions Inc
Canadian Securities Exchange:BNXTView on OTCQB

  • LAST PRICE
    0.3900
  • TODAY'S CHANGE (%)
    0.0100 (2.6316%)
  • Bid / Lots
    0.3900/ 5
  • Ask / Lots
    0.4200/ 11
  • Open / Previous Close
    0.3800 / 0.3800
  • Day Range
    0.3800
    0.3900
  • 52 Week Range
    0.2500
    0.7500
  • Volume
    6,000

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Apr 25, 2024

      Show headlines and story abstract

    • 11:50PM ET on Thursday Apr 25, 2024 by Accesswire
      Companies Mentioned: BNXTF

      NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

      VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to announce that its Cladribine program is advancing to human comparative bioavailability studies in Europe. The Company is reviewing proposals from several contract research organizations to carry out the studies in accordance with EU medical regulatory guidelines. The recent success of both the Company's ODF Cladribine toxicity and comparative pharmacokinetic ("PK") studies and industry interest have set high expectations for the upcoming comparative bioavailability study. Further details on the study will be released in due course.

    • 11:50PM ET on Thursday Apr 25, 2024 by Dow Jones
      Companies Mentioned: BNXT

      NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

      VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to announce that its Cladribine program is advancing to human comparative bioavailability studies in Europe. The Company is reviewing proposals from several contract research organizations to carry out the studies in accordance with EU medical regulatory guidelines. The recent success of both the Company's ODF Cladribine toxicity and comparative pharmacokinetic ("PK") studies and industry interest have set high expectations for the upcoming comparative bioavailability study. Further details on the study will be released in due course.

Peers Headlines